Published in Malar Res Treat on October 11, 2012
Contrasting pediatric and adult cerebral malaria: the role of the endothelial barrier. Virulence (2013) 0.96
Mesenchymal stromal cell therapy attenuated lung and kidney injury but not brain damage in experimental cerebral malaria. Stem Cell Res Ther (2015) 0.82
Endothelial-Leukocyte Interaction in Severe Malaria: Beyond the Brain. Mediators Inflamm (2015) 0.76
Artemisinin inhibits monocyte adhesion to HUVECs through the NF-κB and MAPK pathways in vitro. Int J Mol Med (2016) 0.76
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med (2016) 0.75
The Potential Therapeutic Effects of Artesunate on Stroke and Other Central Nervous System Diseases. Biomed Res Int (2016) 0.75
Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med (2007) 4.22
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
A quantitative assay for intercellular adhesion. Proc Natl Acad Sci U S A (1973) 3.07
A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol (2006) 2.90
The anti-malarial artesunate is also active against cancer. Int J Oncol (2001) 2.56
Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs (1996) 2.20
The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem (1998) 1.99
Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem (1998) 1.92
Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology (2009) 1.87
Artemisinins. Postgrad Med J (2005) 1.66
Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol (2010) 1.65
Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect Immun (2010) 1.47
Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood (2009) 1.46
Quantifying the biophysical characteristics of Plasmodium-falciparum-parasitized red blood cells in microcirculation. Proc Natl Acad Sci U S A (2010) 1.44
Surface co-expression of two different PfEMP1 antigens on single plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1. PLoS Pathog (2010) 1.42
Importance of integrin LFA-1 deactivation for the generation of immune responses. J Exp Med (2005) 1.37
Role of ICAM-1 (CD54) in the development of murine cerebral malaria. Microbes Infect (1999) 1.37
Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-kappaB. Infect Immun (2006) 1.34
Artemisinin Antimalarials: Preserving the "Magic Bullet" Drug Dev Res (2010) 1.25
Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) (2007) 1.23
Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLoS One (2011) 1.18
Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. J Infect Dis (2011) 1.16
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res (2005) 1.14
Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol (2006) 1.13
Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain. Antimicrob Agents Chemother (2011) 1.06
Regulation of endothelial cell adhesion molecule expression in an experimental model of cerebral malaria. Microcirculation (2002) 1.04
Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett (2003) 1.03
Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model. Int J Parasitol (1994) 1.03
The mode of action of the antimalarial artemisinin and its derivatives. Gen Pharmacol (1996) 0.99
Cerebral malaria: a vasculopathy. Am J Pathol (2010) 0.99
Direct activation of human endothelial cells by Plasmodium falciparum-infected erythrocytes. Infect Immun (2005) 0.98
Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology (2004) 0.98
Assessing vascular permeability during experimental cerebral malaria by a radiolabeled monoclonal antibody technique. Infect Immun (2001) 0.97
Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii. Am J Trop Med Hyg (2000) 0.96
Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation. Int Immunopharmacol (2007) 0.92
Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol (2009) 0.90
Design of a new line in treatment of experimental rheumatoid arthritis by artesunate. Immunopharmacol Immunotoxicol (2006) 0.88
Expression of inducible nitric oxide synthase in human umbilical vein endothelial cells during primary culture. Nitric Oxide (2002) 0.86
The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob Agents Chemother (2006) 0.84
Protein kinase C θ deficiency increases resistance of C57BL/6J mice to Plasmodium berghei infection-induced cerebral malaria. Infect Immun (2010) 0.83
Essential role of VLA-4/VCAM-1 pathway in the establishment of CD8+ T-cell-mediated Trypanosoma cruzi-elicited meningoencephalitis. J Neuroimmunol (2003) 0.82
Effects of artemisinin, dihydroartemisinin and arteether on immune responses of normal mice. Int J Immunopharmacol (1990) 0.81
Artesunate and a major metabolite, dihydroartemisinin, diminish mitogen-induced lymphocyte proliferation and activation. Southeast Asian J Trop Med Public Health (2006) 0.79
Reduced in-hospital mortality after improved management of children under 5 years admitted to hospital with malaria: randomised trial. BMJ (2007) 2.71
Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives. Eur J Med Chem (2007) 2.59
In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz (2010) 1.71
Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS Negl Trop Dis (2013) 1.52
Recognition, perceptions and treatment practices for severe malaria in rural Tanzania: implications for accessing rectal artesunate as a pre-referral. PLoS One (2007) 1.43
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis (2013) 1.34
Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J (2010) 1.31
Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis (2012) 1.19
Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther (2014) 1.11
Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis (2013) 1.10
Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis (2008) 1.09
Treatment Options for HIV-Associated Tuberculosis. J Infect Dis (2007) 1.07
Real-time PCR strategy for parasite quantification in blood and tissue samples of experimental Trypanosoma cruzi infection. Acta Trop (2012) 1.03
Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway. Int Immunol (2007) 0.97
Walking for leisure among adults from three Brazilian cities and its association with perceived environment attributes and personal factors. Int J Behav Nutr Phys Act (2011) 0.97
Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2016) 0.93
Lipoxin A4 inhibits acute edema in mice: implications for the anti-edematogenic mechanism induced by aspirin. Prostaglandins Other Lipid Mediat (2006) 0.93
Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1. J Leukoc Biol (2008) 0.92
Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. Expert Rev Anti Infect Ther (2013) 0.90
Cysteinyl-leukotriene type 1 receptors transduce a critical signal for the up-regulation of eosinophilopoiesis by interleukin-13 and eotaxin in murine bone marrow. J Leukoc Biol (2010) 0.89
Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.89
Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in Amazon basin communities. Malar J (2012) 0.88
Frutalin, a galactose-binding lectin, induces chemotaxis and rearrangement of actin cytoskeleton in human neutrophils: involvement of tyrosine kinase and phosphoinositide 3-kinase. Toxicol Appl Pharmacol (2005) 0.85
Mitochondrial localization of non-histone protein HMGB1 during human endothelial cell-Toxoplasma gondii infection. Cell Biol Int (2007) 0.85
Gedunin, a natural tetranortriterpenoid, modulates T lymphocyte responses and ameliorates allergic inflammation. Int Immunopharmacol (2012) 0.84
Activation of human T lymphocytes via integrin signaling induced by RGD-disintegrins. Biochim Biophys Acta (2006) 0.83
Involvement of phosphatidylinositol-3 kinase-Akt and nuclear factor kappa-B pathways in the effect of frutalin on human lymphocyte. Int Immunopharmacol (2005) 0.83
The use of placebo in a trial of rectal artesunate as initial treatment for severe malaria patients en route to referral clinics: ethical issues. J Med Ethics (2010) 0.82
Modulation of inflammatory processes by leaves extract from Clusia nemorosa both in vitro and in vivo animal models. Inflammation (2012) 0.80
Metabonomics reveals drastic changes in anti-inflammatory/pro-resolving polyunsaturated fatty acids-derived lipid mediators in leprosy disease. PLoS Negl Trop Dis (2013) 0.79
Modulation of T lymphocyte and eosinophil functions in vitro by natural tetranortriterpenoids isolated from Carapa guianensis Aublet. Int Immunopharmacol (2010) 0.78
Effects of endothelin ETA receptor antagonism on granulocyte and lymphocyte accumulation in LPS-induced inflammation. J Leukoc Biol (2004) 0.76
Comparison between C57Bl/6 and C57Bl/10 mycobacterial mouse pleurisy with respect to cellular migration and nitric oxide production. Inflammopharmacology (2004) 0.75